257 related articles for article (PubMed ID: 23214419)
21. Functional profiling of p53-binding sites in Hdm2 and Hdmx using a genetic selection system.
Datta S; Bucks ME; Koley D; Lim PX; Savinov SN
Bioorg Med Chem; 2010 Aug; 18(16):6099-108. PubMed ID: 20638853
[TBL] [Abstract][Full Text] [Related]
22. Designing dual inhibitors of Mdm2/MdmX: Unexpected coupling of water with gatekeeper Y100/99.
Lee XA; Verma C; Sim AYL
Proteins; 2017 Aug; 85(8):1493-1506. PubMed ID: 28425639
[TBL] [Abstract][Full Text] [Related]
23. Inhibition of the p53-MDM2 interaction: targeting a protein-protein interface.
Chène P
Mol Cancer Res; 2004 Jan; 2(1):20-8. PubMed ID: 14757842
[TBL] [Abstract][Full Text] [Related]
24. Small-molecule inhibitors of the MDM2-p53 protein-protein interaction to reactivate p53 function: a novel approach for cancer therapy.
Shangary S; Wang S
Annu Rev Pharmacol Toxicol; 2009; 49():223-41. PubMed ID: 18834305
[TBL] [Abstract][Full Text] [Related]
25. Helical beta-peptide inhibitors of the p53-hDM2 interaction.
Kritzer JA; Lear JD; Hodsdon ME; Schepartz A
J Am Chem Soc; 2004 Aug; 126(31):9468-9. PubMed ID: 15291512
[TBL] [Abstract][Full Text] [Related]
26. Regulating the p53 pathway: in vitro hypotheses, in vivo veritas.
Toledo F; Wahl GM
Nat Rev Cancer; 2006 Dec; 6(12):909-23. PubMed ID: 17128209
[TBL] [Abstract][Full Text] [Related]
27. Structure-based design of potent non-peptide MDM2 inhibitors.
Ding K; Lu Y; Nikolovska-Coleska Z; Qiu S; Ding Y; Gao W; Stuckey J; Krajewski K; Roller PP; Tomita Y; Parrish DA; Deschamps JR; Wang S
J Am Chem Soc; 2005 Jul; 127(29):10130-1. PubMed ID: 16028899
[TBL] [Abstract][Full Text] [Related]
28. Identification of a Structural Determinant for Selective Targeting of HDMX.
Ben-Nun Y; Seo HS; Harvey EP; Hauseman ZJ; Wales TE; Newman CE; Cathcart AM; Engen JR; Dhe-Paganon S; Walensky LD
Structure; 2020 Jul; 28(7):847-857.e5. PubMed ID: 32359398
[TBL] [Abstract][Full Text] [Related]
29. MDM2/MDMX inhibitor peptide: WO2008106507.
Macchiarulo A; Pellicciari R
Expert Opin Ther Pat; 2009 May; 19(5):721-6. PubMed ID: 19441944
[TBL] [Abstract][Full Text] [Related]
30. Identification of novel mdm2 binding peptides by phage display.
Böttger V; Böttger A; Howard SF; Picksley SM; Chène P; Garcia-Echeverria C; Hochkeppel HK; Lane DP
Oncogene; 1996 Nov; 13(10):2141-7. PubMed ID: 8950981
[TBL] [Abstract][Full Text] [Related]
31. Structure of a stapled peptide antagonist bound to nutlin-resistant Mdm2.
Chee SM; Wongsantichon J; Soo Tng Q; Robinson R; Joseph TL; Verma C; Lane DP; Brown CJ; Ghadessy FJ
PLoS One; 2014; 9(8):e104914. PubMed ID: 25115702
[TBL] [Abstract][Full Text] [Related]
32. p53 alpha-Helix mimetics antagonize p53/MDM2 interaction and activate p53.
Chen L; Yin H; Farooqi B; Sebti S; Hamilton AD; Chen J
Mol Cancer Ther; 2005 Jun; 4(6):1019-25. PubMed ID: 15956260
[TBL] [Abstract][Full Text] [Related]
33. Adenoviral E1A targets Mdm4 to stabilize tumor suppressor p53.
Li Z; Day CP; Yang JY; Tsai WB; Lozano G; Shih HM; Hung MC
Cancer Res; 2004 Dec; 64(24):9080-5. PubMed ID: 15604276
[TBL] [Abstract][Full Text] [Related]
34. Mouse double minute antagonist Nutlin-3a enhances chemotherapy-induced apoptosis in cancer cells with mutant p53 by activating E2F1.
Ambrosini G; Sambol EB; Carvajal D; Vassilev LT; Singer S; Schwartz GK
Oncogene; 2007 May; 26(24):3473-81. PubMed ID: 17146434
[TBL] [Abstract][Full Text] [Related]
35. Structure-activity studies of Mdm2/Mdm4-binding stapled peptides comprising non-natural amino acids.
Chee SMQ; Wongsantichon J; Siau J; Thean D; Ferrer F; Robinson RC; Lane DP; Brown CJ; Ghadessy FJ
PLoS One; 2017; 12(12):e0189379. PubMed ID: 29228061
[TBL] [Abstract][Full Text] [Related]
36. Molecular pathways: targeting Mdm2 and Mdm4 in cancer therapy.
Li Q; Lozano G
Clin Cancer Res; 2013 Jan; 19(1):34-41. PubMed ID: 23262034
[TBL] [Abstract][Full Text] [Related]
37. Recognition Dynamics of p53 and MDM2: Implications for Peptide Design.
ElSawy KM; Lane DP; Verma CS; Caves LS
J Phys Chem B; 2016 Jan; 120(2):320-8. PubMed ID: 26701330
[TBL] [Abstract][Full Text] [Related]
38. Expansion of protein interaction maps by phage peptide display using MDM2 as a prototypical conformationally flexible target protein.
Burch L; Shimizu H; Smith A; Patterson C; Hupp TR
J Mol Biol; 2004 Mar; 337(1):129-45. PubMed ID: 15001357
[TBL] [Abstract][Full Text] [Related]
39. Molecular mechanism of the interaction between MDM2 and p53.
Schon O; Friedler A; Bycroft M; Freund SM; Fersht AR
J Mol Biol; 2002 Oct; 323(3):491-501. PubMed ID: 12381304
[TBL] [Abstract][Full Text] [Related]
40. RNAi knockdown of HdmX or Hdm2 leads to new insights into p53 signaling.
Berberich SJ
Cell Cycle; 2010 Sep; 9(18):3640-1. PubMed ID: 20855947
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
